Didier Blaise, MD, PhD, Paoli-Calmettes Institute, Marseille, France, shares some insights into the current challenges of stem cell transplantation (SCT) and cellular therapy for myeloid malignancies, commenting on the role of age, and discussing the idea of introducing cellular therapy in earlier lines of therapy (LOT). This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.